

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 23.06A of the Rules Governing the Listing of Securities on GEM (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited.

The board (the “**Board**”) of directors (the “**Directors**”) of Huakang Biomedical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that on 9 April 2020, a total of 26,008,000 share options (the “**Share Options**”) to subscribe for the ordinary shares of par value of HK\$0.01 each of the Company (the “**Shares**”) were granted to executive Directors and certain employees (the “**Grantees**”) of the Group, subject to the acceptance of the Grantees, by the Company pursuant to the share option scheme adopted by the Company on 13 January 2020 (the “**Share Option Scheme**”). Details of the Share Options granted are as follows:

Date of grant	: 9 April 2020 (the “ Date of Grant ”)
Number of Share Options granted	: 26,008,000 Share Options (each Share Option shall entitle the holder thereof to subscribe for one Share)
Closing price of the Shares on the Date of Grant	: 0.125 per Share
Exercise price of Share Options granted	: 0.125 per Share, which represents the highest of (i) 0.125 being the closing price of the Shares as stated in the daily quotations sheet issued by the Stock Exchange on the Date of Grant; (ii) 0.125, being the average of the closing prices of the Shares as stated in the daily quotations sheet issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) HK\$0.01, being the nominal value of the Share.
Consideration for the grant of the Share Options	: HK\$1 to be paid by each of the Grantees upon acceptance of the Share Options granted
Validity period of the Share Options	: The Share Options granted shall be valid and exercisable in whole or in part from the date of the acceptance of the Option(s) for a period of ten years from the Date of Grant

Among the total of 26,008,000 Share Options granted, 16,000,000 Share Options were granted to the following executive Directors:

<u>Name</u>	<u>Position/Relationship</u>	<u>Number of Share Options granted</u>
Zhang Shuguang	Executive Director, chairman of the Board and a substantial shareholder of the Company	4,000,000
Zhang Chunguang	Executive Director and chief executive officer	4,000,000
Poon Lai Yin Michael	Executive Director, chief financial officer and compliance officer	4,000,000
He Jiaming	Executive Director and business development director	4,000,000
Total		<u>16,000,000</u>

In accordance with Rule 23.04(1) of the GEM Listing Rules and the Share Option Scheme, the grants of Share Options by the Company to above Grantee who are either executive Directors, chief executive and/or substantial shareholder of the Company or any of their respective associates (as defined in the GEM Listing Rules) have been approved by the independent non-executive Directors.

Save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company, or any of their respective associate (as defined in the GEM Listing Rules) at the date of the announcement.

Given that the grant of Share Options to each of the Grantees will not result in the Shares issued and to be issued upon exercise of all Share Options already granted and to be granted (including Share Options exercised and outstanding) to each of the Grantees, collectively in the 12-month period up to and including the Date of Grant, representing in aggregate over (a) 1% of the Shares in issue pursuant to Rule 23.03(4) of the GEM Listing Rules; and (b) 0.1% of the Shares in issue and having an aggregate value, based on the closing price of the Shares at the Date of Grant, in excess of HK\$5 million pursuant to Rule 23.04(1) of the GEM Listing Rules, the grant of Share Options to the Grantees is not required to be approved by the shareholders of the Company at general meeting.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 9 April 2020

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Yeung David Wai Chow, Mr. Kwok Chi Shing and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.